MANAMAURI, the High-Quality Energy Drink Brand, Joins EastBridge Global Investments for Major International Expansion
The acquisition will fuel Manamauri's global expansion with new production facilities, extended product lines, and a continued commitment to supporting emerging sports.
BRUSSELS, BELGIUM / ACCESSWIRE / November 8, 2024 / MANAMAURI, the energy drink brand known for its commitment to high quality and smart pricing, has officially finalized an acquisition agreement with a subsidiary of EastBridge Global Investments. This strategic partnership empowers MANAMAURI to scale globally, remaining true to its founding values of exceptional product standards, accessibility, and support for emerging sports talent.
MANAMAURI LOGO
MANAMAURI LOGO
"MANAMAURI was established with a clear mission: to deliver premium energy products with an intelligent pricing model, making quality accessible without compromising our values," shared a spokesperson for MANAMAURI. "We've managed to grow steadily while maintaining lean operations, focusing on efficient structures that keep unnecessary costs low. The success we've achieved in just a few years has inspired us to embrace a larger, global vision."
The transition of ownership has been completed, with the support of the original shareholders, who remain available to provide assistance to the new management as needed. This ensures a seamless continuation of MANAMAURI's operations and strategic direction. To drive this expansion, EastBridge has ambitious plans to establish three new production facilities in Africa, the Middle East, and Asia. These new facilities will boost MANAMAURI's production capacity while fostering community development and employment opportunities in regions with high growth potential, such as Africa. MANAMAURI has long invested in visibility across various sports, strengthening its presence beyond just motorsports.
In addition to a GT3 endurance racing team that won last year's Middle East Endurance Championship (where the majority of ownership remains with South American stakeholders), MANAMAURI has steadily expanded its involvement to include football, mountaineering, volleyball, and motocross. By supporting skilled athletes in underrepresented or emerging sports, the brand remains committed to elevating sports that often receive limited sponsorship and recognition.
As part of its growth strategy, MANAMAURI will soon launch a new product line that continues its dedication to natural and sustainable choices, aligned with EastBridge's commitment to responsible business practices. The upcoming products include:
Vitamin Water: delivering a quick, healthy recharge using only the finest natural ingredients.
Pre-workout Drink: formulated to support peak performance with a blend of natural and essential nutrients.
Mineral Supplements: focused on hydration and recovery, derived from premium, natural mineral sources.
High-Quality Fruit Juices: crafted with 100% natural ingredients, free from artificial additives or preservatives, providing a pure, energizing experience that embodies MANAMAURI's core values.
About MANAMAURI
Founded with a vision to bring high-quality energy products to market at a fair, accessible price, MANAMAURI has gained significant traction for its innovative, efficient approach to product quality and pricing. With EastBridge Global Investments on board, MANAMAURI is ready to expand internationally while staying true to its roots and dedication to supporting emerging athletic talent.
About EastBridge Global Investments
EastBridge Global Investments focuses on supporting the sustainable growth of emerging brands across Asia, Africa, and the Middle East. By providing targeted resources and industry connections, EastBridge empowers brands like MANAMAURI to reach new heights while upholding their founding principles.
Contact Information
Alistair Vaughn
MARKETING AND MEDIA
marketing@manamauri.com
+13107421384
SOURCE: MANAMAURI ENERGY
View the original press release on newswire.com.
manamauri trading
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom